KR100281450B1 - 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체 - Google Patents

엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체 Download PDF

Info

Publication number
KR100281450B1
KR100281450B1 KR1019940704065A KR19940704065A KR100281450B1 KR 100281450 B1 KR100281450 B1 KR 100281450B1 KR 1019940704065 A KR1019940704065 A KR 1019940704065A KR 19940704065 A KR19940704065 A KR 19940704065A KR 100281450 B1 KR100281450 B1 KR 100281450B1
Authority
KR
South Korea
Prior art keywords
oxo
amino
carboxylic acid
octahydro
phenylpropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940704065A
Other languages
English (en)
Korean (ko)
Other versions
KR950701634A (ko
Inventor
개리 에이 플린
패트릭 더블유. 셤
Original Assignee
슈테펜 엘. 네스비트
메렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈테펜 엘. 네스비트, 메렐 다우 파마슈티칼스 인크. filed Critical 슈테펜 엘. 네스비트
Publication of KR950701634A publication Critical patent/KR950701634A/ko
Application granted granted Critical
Publication of KR100281450B1 publication Critical patent/KR100281450B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1019940704065A 1992-05-15 1993-04-21 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체 Expired - Fee Related KR100281450B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US88496392A 1992-05-15 1992-05-15
US884,963 1992-05-15
US884963 1992-05-15
US4000393A 1993-04-09 1993-04-09
US40003 1993-04-09
US040,003 1993-04-09
PCT/US1993/003721 WO1993023403A1 (en) 1992-05-15 1993-04-21 NOVEL MERCAPTOACETYLAMIDO PYRIDAZO[1,2]PYRIDAZINE, PYRAZOLO[1,2]PYRIDAZINE, PYRIDAZO[1,2-a][1,2]DIAZEPINE AND PYRAZOLO[1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE

Publications (2)

Publication Number Publication Date
KR950701634A KR950701634A (ko) 1995-04-28
KR100281450B1 true KR100281450B1 (ko) 2001-02-01

Family

ID=26716641

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704065A Expired - Fee Related KR100281450B1 (ko) 1992-05-15 1993-04-21 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체

Country Status (19)

Country Link
US (1) US5366973A (enExample)
EP (1) EP0640086B1 (enExample)
JP (1) JP3360079B2 (enExample)
KR (1) KR100281450B1 (enExample)
AT (1) ATE182892T1 (enExample)
AU (1) AU669364B2 (enExample)
CA (1) CA2133963C (enExample)
DE (1) DE69325904T2 (enExample)
DK (1) DK0640086T3 (enExample)
ES (1) ES2138622T3 (enExample)
FI (1) FI108230B (enExample)
GR (1) GR3031287T3 (enExample)
HU (1) HU223663B1 (enExample)
IL (1) IL105680A (enExample)
MX (1) MX9302824A (enExample)
NO (1) NO302573B1 (enExample)
NZ (1) NZ251930A (enExample)
TW (1) TW270115B (enExample)
WO (1) WO1993023403A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
WO1994028901A1 (en) * 1993-06-11 1994-12-22 Eisai Co., Ltd. Amino acid derivative
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
EP0745081B1 (en) * 1994-02-14 2001-11-21 Merrell Pharmaceuticals Inc. indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
JP3561753B2 (ja) * 1994-02-14 2004-09-02 メレル ファーマスーティカルズ インコーポレーテッド エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規な２−置換インダン−２−メルカプトアセチルアミドジスルフィド誘導体類
NZ279397A (en) * 1994-02-14 1997-08-22 Merrell Pharma Inc Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
PT751783E (pt) * 1994-03-24 2000-05-31 Merrell Pharma Inc Derivados aminoacetilmercapto hipocolesterolemicos antiateroscleroticos e hipotrigliceridemicos
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US6699869B1 (en) 1995-03-24 2004-03-02 Myriad Genetics Inc. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6020331A (en) * 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6245764B1 (en) 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5877313A (en) * 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
EP1053246B1 (en) * 1998-02-12 2003-01-02 Molecumetics, Ltd. Beta-sheet mimetics and methods relating to the use thereof
IT1298268B1 (it) * 1998-02-18 1999-12-20 Zambon Spa Procedimento per la preparazione dell'acido (s)-2-bromo-3-fenil- propionico
FR2777889B1 (fr) 1998-04-27 2004-07-09 Hoechst Marion Roussel Inc Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs
CA2332608C (en) 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6177565B1 (en) * 1998-08-19 2001-01-23 Vertex Pharmaceuticals Inc. Process for synthesizing piperazic acid
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EE05670B1 (et) * 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
US6821971B2 (en) * 2001-09-20 2004-11-23 The Procter & Gamble Company Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
US6984645B2 (en) * 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7053214B2 (en) 2002-02-14 2006-05-30 Myriad Genetics, Inc. β-sheet mimetics and composition and methods relating thereto
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
EP2334671A1 (en) 2008-06-24 2011-06-22 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN106674228B (zh) * 2016-12-09 2018-12-04 河南农业大学 多元杂环化合物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334095A (en) * 1965-02-16 1967-08-01 Sandoz Ag Novel pyrrolo-oxazines and pyrrolo-oxazoles
US3334091A (en) * 1965-03-25 1967-08-01 Sandoz Ag Sedatives
GB1525845A (en) * 1976-07-30 1978-09-20 Ucb Sa 1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
IE50839B1 (en) * 1980-02-26 1986-07-23 Wyeth John & Brother Ltd Novel processes for preparing proline derivatives and analogous compounds
EP0042100A1 (de) * 1980-06-13 1981-12-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
ZA833214B (en) * 1982-05-12 1983-12-28 Hoffmann La Roche Bicyclic compounds
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4552889A (en) * 1983-06-09 1985-11-12 Eli Lilly And Company 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4692438A (en) * 1984-08-24 1987-09-08 Hoffmann-La Roche Inc. Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
CA1274832A (en) * 1985-04-30 1990-10-02 Richard Elmer Holmes 7-substituted bicyclic pyrazolidinones
ZA874107B (enExample) * 1986-06-13 1987-12-09
US4973585A (en) * 1986-06-13 1990-11-27 Merrell Dow Pharmaceuticals Tricyclic lactams active as antihypertensive agents
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
GB8629875D0 (en) * 1986-12-15 1987-01-28 Hoffmann La Roche Pyridazodiazepine derivatives
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use
GB8926512D0 (en) * 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
WO1991009840A1 (en) * 1989-12-22 1991-07-11 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
EP0492369B1 (en) * 1990-12-21 1997-09-17 Merrell Pharmaceuticals Inc. Novel amino and nitro containing tricyclic compounds useful as inhibitors of ace
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
EP0533084A1 (en) * 1991-09-16 1993-03-24 Schering Corporation Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation

Also Published As

Publication number Publication date
DE69325904T2 (de) 1999-12-09
AU4033293A (en) 1993-12-13
IL105680A (en) 1998-01-04
ES2138622T3 (es) 2000-01-16
NO944335D0 (no) 1994-11-14
JPH07506832A (ja) 1995-07-27
AU669364B2 (en) 1996-06-06
EP0640086B1 (en) 1999-08-04
KR950701634A (ko) 1995-04-28
NO302573B1 (no) 1998-03-23
DE69325904D1 (de) 1999-09-09
ATE182892T1 (de) 1999-08-15
MX9302824A (es) 1994-05-31
CA2133963C (en) 1998-07-07
EP0640086A1 (en) 1995-03-01
GR3031287T3 (en) 1999-12-31
NO944335L (no) 1995-01-13
DK0640086T3 (da) 1999-12-06
JP3360079B2 (ja) 2002-12-24
FI108230B (fi) 2001-12-14
HUT71099A (en) 1995-11-28
IL105680A0 (en) 1993-09-22
FI945363L (fi) 1994-11-14
HU223663B1 (hu) 2004-11-29
NZ251930A (en) 1996-02-27
FI945363A0 (fi) 1994-11-14
WO1993023403A1 (en) 1993-11-25
CA2133963A1 (en) 1993-11-25
US5366973A (en) 1994-11-22
TW270115B (enExample) 1996-02-11

Similar Documents

Publication Publication Date Title
KR100281450B1 (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체
KR100372491B1 (ko) 엔케팔리나제및ace의억제제로서유용한신규메르캅토아세틸아미드유도체
KR100271242B1 (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 2-치환 인단-2-카르복시알킬 유도체
KR100273734B1 (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 카르복시알킬 유도체
US5635502A (en) Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ACE
KR100281608B1 (ko) 4-머캅토아세틸아미노-(2)벤즈아제핀온(3) 유도체 및 이의 제조방법.
KR100220879B1 (ko) 안지오텐신 전환 효소 억제제로서 유용한 신규 아미노 및 니트로 함유 트리시클릭 화합물
KR100348949B1 (ko) 엔케팔리나제의억제제로서유용한신규의인단-2-머캅토아세틸아미드디술파이드유도체
KR100357354B1 (ko) 엔케팔리나제및안지오텐신전환효소(ace)의억제제로서유용한신규의머캅토아세틸아미드디설파이드유도체
US5527795A (en) Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP3561753B2 (ja) エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規な２−置換インダン−２−メルカプトアセチルアミドジスルフィド誘導体類

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20041109

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20051118

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20051118

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000